Forthcoming Issues
Sports Cardiology (Source: Cardiology Clinics)
Source: Cardiology Clinics - October 7, 2022 Category: Cardiology Source Type: research
Key Phenotypes of Heart Failure with Preserved Ejection Fraction
Pathophysiological heterogeneity is considered the primary reason for the limited effective treatment options for patients with heart failure with preserved ejection fraction (HFpEF). Recent studies have focused on HFpEF phenotyping that categorizes patients as pathophysiologically homogeneous groups to develop personalized treatment strategies. This approach relies on comorbidities, cardiac structure and function, central hemodynamics at rest and during exercise, or machine learning techniques. Although some phenotypes have been successfully identified, efforts are still ongoing. This review summarizes the current underst...
Source: Cardiology Clinics - September 14, 2022 Category: Cardiology Authors: Kazuki Kagami, Tomonari Harada, Hideki Ishii, Masaru Obokata Source Type: research
Nonpharmacological Strategies in Heart Failure with Preserved Ejection Fraction
Patients with heart failure with preserved ejection fraction (HFpEF) suffer from a high rate of cardiometabolic comorbidities with limited pharmaceutical therapies proven to improve clinical outcomes and cardiorespiratory fitness (CRF). Nonpharmacologic therapies, such as exercise training and dietary interventions, are promising strategies for this population. The aim of this narrative review is to present a summary of the literature published to date and future directions related to the efficacy of nonpharmacologic, lifestyle-related therapies in HFpEF, with a focus on exercise training and dietary interventions (Source: Cardiology Clinics)
Source: Cardiology Clinics - September 14, 2022 Category: Cardiology Authors: Natalie J. Bohmke, Hayley E. Billingsley, Danielle L. Kirkman, Salvatore Carbone Source Type: research
Device Therapy for Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with few options for effective pharmacologic therapies. Numerous device-based approaches to HFpEF therapy have emerged, which aim to treat the clinical and pathophysiologic features common to the varied causes of this syndrome. This review summarizes the current landscape of device therapy in HFpEF with a focus on structural interventions, such as left-to-right atrial shunts; cardiac contractility modulation; autonomic modulation, such as baroreflex activation therapy and splanchnic nerve modulation; and respiratory modulation, such as phren...
Source: Cardiology Clinics - September 14, 2022 Category: Cardiology Authors: Husam M. Salah, Allison P. Levin, Marat Fudim Source Type: research
Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a common medical condition associated with increased morbidity and mortality. Through different mechanisms, including passive left-sided congestion and/or vasculopathy, patients with HFpEF can develop pulmonary hypertension (PH). This association -PH-HFpEF- is linked with worsening symptomatology and long-term outcomes. Although pulmonary vasodilators have been effective in treating patients with a pulmonary vasculopathy, such as pulmonary arterial hypertension (PAH), these results have not been replicated in those with PH-HFpEF. There is an unmet need to develop ef...
Source: Cardiology Clinics - September 14, 2022 Category: Cardiology Authors: Victor M. Moles, Gillian Grafton Source Type: research
Transthyretin Cardiac Amyloidosis
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, and cardiac amyloidosis (CA) is one of the causes of HFpEF, that has established and emerging treatment options. However, it remains an underdiagnosed and often overlooked cause of HFpEF. The importance of early diagnosis cannot be emphasized enough, as emerging therapies are more effective early in the course of the disease. Further, because of the unique physiologic and hemodynamic features of CA, patients poorly tolerate traditional heart failure medications and experience worse outcomes compared with other causes of HFpEF. With the agin...
Source: Cardiology Clinics - September 14, 2022 Category: Cardiology Authors: Dia A. Smiley, Carlos M. Rodriguez, Mathew S. Maurer Source Type: research
Approach to Echocardiography in Heart Failure with Preserved Ejection Fraction
As echocardiography is universally performed in the evaluation of suspected heart failure with preserved ejection fraction (HFpEF), a number of structural and functional characteristics relevant to both the diagnosis and phenotyping of HFpEF can be elucidated. Exclusion of alternate causes of heart failure is a critical first step performed principally by echocardiography. Once HFpEF is confirmed, echocardiography may provide insight into pathophysiology and phenotyping by quantifying atrial mechanics, pericardial restraint, degree of pulmonary hypertension, and atrial valvular regurgitation. Although current echo-Doppler ...
Source: Cardiology Clinics - September 14, 2022 Category: Cardiology Authors: C. Charles Jain, Yogesh N.V. Reddy Source Type: research
Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction
The management of heart failure with preserved ejection fraction (HFpEF) is rapidly evolving. The pharmacologic treatment of patients with HFpEF includes symptom management with diuretics and optimization of comorbidities, including hypertension, obesity, diabetes mellitus, and atrial fibrillation. Specific therapies, including angiotensin II receptor blockers, mineralocorticoid receptor antagonists, angiotensin receptor –neprilysin inhibitors, and sodium–glucose cotransporter-2 inhibitors, are well tolerated and can reduce the risk of HF hospitalization, particularly in those on the lower end of the HFpEF left ventric...
Source: Cardiology Clinics - September 7, 2022 Category: Cardiology Authors: Anthony E. Peters, Adam D. DeVore Source Type: research
Geriatric Domains in Patients with Heart Failure with Preserved Ejection Fraction
Because heart failure with preserved ejection fraction (HFpEF) is closely linked to aging processes and disproportionately affects older adults, consideration of geriatric domains is paramount to ensure high-quality care to older adults with HFpEF. Multimorbidity, polypharmacy, cognitive impairment, depressive symptoms, frailty, falls, and social isolation each have important implications on quality of life and clinical events including hospitalization and mortality. There are multiple strategies to screen for these conditions. This narrative review underscores the importance of screening for multiple geriatric conditions,...
Source: Cardiology Clinics - September 3, 2022 Category: Cardiology Authors: Parag Goyal, Omar Zainul, Dylan Marshall, Dalane W. Kitzman Source Type: research
The Role of Multimodality Imaging in the Evaluation of Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, affecting approximately half of all patients with HF. The diagnosis of HFpEF can be notoriously challenging in clinical practice, given the many overlapping etiologies of dyspnea or reduced exercise tolerance in patients at risk for HFpEF. Multimodality imaging has an important role in establishing the diagnosis of HFpEF and the presence of elevated left ventricular filling pressures, identifying specific etiologies of HFpEF that can benefit from approved therapies, and discerning distinct phenogroups or mechanistic abnormalities that may inform th...
Source: Cardiology Clinics - September 1, 2022 Category: Cardiology Authors: Mahesh K. Vidula, Paco E. Bravo, Julio A. Chirinos Source Type: research
Covid-19
CARDIOLOGY CLINICS (Source: Cardiology Clinics)
Source: Cardiology Clinics - July 16, 2022 Category: Cardiology Authors: Timothy D. Henry, Santiago Garcia Source Type: research
Copyright
ELSEVIER (Source: Cardiology Clinics)
Source: Cardiology Clinics - July 16, 2022 Category: Cardiology Source Type: research
Contributors
JAMIL A. ABOULHOSN, MD, FACC, FSCAI (Source: Cardiology Clinics)
Source: Cardiology Clinics - July 16, 2022 Category: Cardiology Source Type: research
Contents
Timothy D. Henry and Santiago Garcia (Source: Cardiology Clinics)
Source: Cardiology Clinics - July 16, 2022 Category: Cardiology Source Type: research
Forthcoming Issues
Heart Failure with Preserved Ejection Fraction (Source: Cardiology Clinics)
Source: Cardiology Clinics - July 16, 2022 Category: Cardiology Source Type: research
